GI Oncology
Advertisement
Dr. Pant describes the improved DOR and median OS seen with the treatment, and discusses the ongoing phase 3 trial.
The approval is based on positive results of the CodeBreaK300 trial, which demonstrated an improvement in PFS.
Dr. Cytryn reviews the FDA approval of tislelizumab and shares thoughts on its clinical impact.
The peripheral blood transcriptome of NET patients showed differential enrichment of 30 systemic cancer hallmarks.
Drs. Finn and Yopp discuss adjuvant therapy in HCC following surgical resection in a review of data from IMbrave050.
Adding a taxane to the standard regimen of gemcitabine/cisplatin does not improve OS in patients with newly diagnosed BTC.
Drs. Finn and Yopp discuss the IMbrave050 study for early-stage HCC, including the trial design, results, and implications.
A recent study reviewed global disparities in gastric cancer screening, finding limited research about screening feasibility.
A recent study showed evidence that HBV infection facilitates drug resistance in cancer treatment medications.
Tislelizumab is a monoclonal antibody with a high affinity and binding specificity against programmed cell death protein 1.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
SBRT with sorafenib is shown to be associated with a clinically important but not statistically significant improved OS rate.
Data on growing pancreatic cancer cases in young Americans shows that some cases are misattributed as early endocrine cancer.
A recent study utilized patient data from 13 medical centers in a biomarker analysis of 1L ICIs with & without ...
A recent observational study determined if there is a correlation between the improvement of ADR and lower rates of CRC.
The designation is based on positive results from an ongoing collaborative trial between GSK and MSK Cancer Center.
Dr. Joseph Cullen discusses the combination of vitamin C with gemcitabine and nab-paclitaxel for pancreatic cancer.
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
Rising HCC mortality rates in the US highlight stark disparities across age, sex, race, and liver disease etiologies.
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.